Figure 3.

Therapeutic Targeting of SCD1 in Preclinical GBM Mouse Models

(A) Overview of experimental setup.

(B–D) Mice implanted with 83-Fluc GSCs (2 × 10⁴; n = 8/group) received a daily intranasal dose of DMSO (Control) or CAY (5 mg/kg) for 10 days. (B) Overtime monitoring of tumor growth with Fluc imaging in individual mice from Ctrl and CAY-treated groups. Hash depicts the time of death due to tumor burden. (C) Ki67 immunostaining in one Ctrl and one CAY-treated mouse. Scale bar, 100 μm. (D) Kaplan-Meier curves showing median survival in both groups (^∗p = 0.008, two-sided log-rank test).

(E–G) Mice implanted with 157-Fluc GSCs (1 × 10⁵; n = 8/group) were treated with vehicle or CAY (5 mg/kg). (E) Overtime Fluc imaging demonstrates the absence of tumor growth in all eight CAY-treated mice. (F) Survival curves in both groups (p = 0.0002; two-sided log-rank test). (G) The ratio of liver weight to the body weight in both experimental groups is shown. ns, non-significant by Student’s t test.

See also Figure S3.